Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 11/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | ACTR2 | P61160 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | FPR3 | P25089 | 1/20 | 0.35 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059535 | 1.00 | CCR1 (0.51) | CCR1SLC6A3MAPK11MAPK14MAPK13 | |
| SCHEMBL5059522 | 1.00 | CCR1 (0.51) | CCR1SLC6A3MAPK11MAPK14MAPK13 | |
| SCHEMBL5065956 | 0.90 | CCR1 (0.49) | CCR1MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5065954 | 0.90 | CCR1 (0.49) | CCR1MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5065951 | 0.90 | CCR1 (0.49) | CCR1MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5066468 | 0.87 | CCR1 (0.51) | CCR1MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5066470 | 0.87 | CCR1 (0.51) | CCR1MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5066465 | 0.87 | CCR1 (0.51) | CCR1MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5061149 | 0.87 | CCR1 (0.47) | CCR1MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5061148 | 0.87 | CCR1 (0.47) | CCR1MAPK11MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | claimed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | CCR1 4304/4885SLC6A3 4415/4885MAPK11 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.